Company profile
Making Proteins Accessible | Nuclera
Rapid protein prototyping, making proteins accessible its what we do. Its what we deliver. Click here to learn more.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
MA | Transaction MzQ0MjM2NTE5NGFkaXF6a2N4 | Paper/PDF filed
Published 19 Nov 2024 10:39
RESOLUTIONS | Transaction WURGRUNQMzdhZGlxemtjeA | Paper/PDF filed
Published 19 Nov 2024 10:33
SH01 | Transaction MzQ0MjM3MTIyNmFkaXF6a2N4
Published 08 Nov 2024 10:48
SH01 | Transaction MzQ0MjM2NDU1NGFkaXF6a2N4
Published 07 Nov 2024 11:40
AA | Transaction MzQ0MTU5MTg5OGFkaXF6a2N4 | Paper/PDF filed
Published 01 Nov 2024 12:24
CS01 | Transaction MzQzNTk3OTYxNWFkaXF6a2N4
Published 16 Sep 2024 09:27
SH01 | Transaction MzQzNTMwNjEyNmFkaXF6a2N4
Published 11 Sep 2024 16:11
MA | Transaction MzQzMzY1MDI1NGFkaXF6a2N4 | Paper/PDF filed
Published 03 Sep 2024 07:02
RESOLUTIONS | Transaction WURBRlBUVExhZGlxemtjeA | Paper/PDF filed
Published 03 Sep 2024 07:01
TM01 | Transaction MzQzMzY0OTQ0M2FkaXF6a2N4
Published 28 Aug 2024 14:12
TM01 | Transaction MzQzMzY0OTQ0NWFkaXF6a2N4
Published 28 Aug 2024 14:12
AP01 | Transaction MzQzMzY0OTQ1M2FkaXF6a2N4
Published 28 Aug 2024 14:12
TM01 | Transaction MzQzMzY0OTQ0OGFkaXF6a2N4
Published 28 Aug 2024 14:12
Company registered at Companies House
1 Apr 2024 to 31 Mar 2026
Nuclera is a world-leader in the nascent space of active-matrix thin-film-transistor digital-microfluidics. Nuclera is developing a cutting-edge rapid protein prototyping/synthesising platform, eProteinDiscovery(TM). Industry partners (CROs/SMEs/large-pharma) have shown a desire to have fast protein access, automated and in-house to address this key chall...
1 Feb 2024 to 31 Jan 2025
In this project we will adapt eProtein, the rapid protein prototyper, to express membrane proteins, meeting the high demand across the engineering biology landscape. Current methods pose a major R&D bottleneck due to slow, costly processes, but Nuclera's eProtein innovation offers a fast, automated, and in-house solution, reducing timelines and costs for ...
1 Nov 2023 to 30 Sep 2025
Protein kinases are involved in almost all bodily function and changes in their activity can give rise to cancer and other diseases. Nevertheless, few drugs exist that target kinases as they are considered "difficult to drug" by leading experts. Recently, DNA Encoded Small Molecule Libraries (DELs) have attracted attention due to their ability to enable s...
1 Jul 2015 to 31 Dec 2016
Nuclera Nucleics Ltd is a Cambridge-based biotech start-up transforming the life sciences through the development of a next generation DNA synthesis platform. Nuclera was founded by four enterprising scientists determined to improve the slow and expensive process of obtaining long pieces of biologically relevant DNA. Through our novel, biologically-inspir...
1 Jul 2014 to 30 Jun 2015
Nuclera Nucleics Ltd is a Cambridge-based biotech startup transforming the life sciences through the development of a next generation DNA synthesis platform. Nuclera was founded by four enterprising scientists determined to improve the slow and expensive process of obtaining long pieces of biologically relevant DNA. Through our novel, biologically-inspire...
